Are these panels validated for clinical CRS grading or management?

No. All CAR-T panels are for research use only (RUO). They are suitable for preclinical CAR-T development, correlative research in clinical trials, and biomarker discovery. They are not validated for clinical CRS grading, tocilizumab administration decisions, or individual patient management. CRS grading and management should follow established clinical criteria (ASTCT grading) and institutional protocols.

Which panel should I use for CRS monitoring?

The CAR-T 7-Plex Panel 2 (GM-CSF, IFN-γ, IL-10, IL-6, TNF-α, IL-1β, MCP-1) provides the most focused CRS cytokine coverage. The 8-Plex adds Granzyme B, Perforin, IL-2, IL-12p70, and IP-10 — providing effector function and innate activation data alongside CRS markers. Many programs run both: Panel 2 for focused CRS monitoring at every timepoint, with the 8-Plex at key timepoints (pre-infusion, peak CRS, Day 14, Day 28) for deeper biological characterization.

How should I design the serial sampling schedule for CAR-T monitoring?

A typical CAR-T monitoring schedule includes: Pre-infusion baseline (Day 0 pre-infusion); Early expansion phase (Days 1, 3, 5, 7 post-infusion) — capturing CRS onset and peak; Late expansion/contraction (Days 10, 14, 21, 28) — capturing CRS resolution and CAR-T persistence; Long-term monitoring (Months 2, 3, 6, 12) — capturing long-term CAR-T persistence, B-cell recovery, and late effects. The highest-frequency sampling (daily or every-other-day) should span the expected CRS window (Days 1–10). 25 µL per panel enables running multiple panels at each timepoint from a single blood draw. Contact us to design a sampling schedule tailored to your CAR-T product and clinical protocol.

Home
Platform
MSD Multiplex Assay Services
MSD CAR-T Cell Therapy Monitoring

CAR-T Cell Research

CRS Cytokines · Immune Checkpoint · Effector Function

MSD CAR-T Cell Research Monitoring Services

Characterize CAR-T cell activation, expansion, cytokine release, checkpoint dynamics, and cytotoxic effector function using MSD multiplex panels — four pre-configured configurations spanning 7 to 9 analytes from 25 µL of plasma, each targeting a distinct dimension of CAR-T biology.

CAR-T cell research generates the most information-dense biomarker data in immunology — activated CAR-T cells expand rapidly, secrete cytokines that drive systemic inflammatory responses, upregulate checkpoint proteins that may signal functional exhaustion, and release Granzyme B and Perforin as direct evidence of target cell killing. These processes span three interconnected biological dimensions that no single-analyte measurement captures adequately. Our four CAR-T monitoring panels — two 7-plex configurations targeting either checkpoint dynamics or CRS cytokines, an 8-plex adding cytotoxic effector readouts, and a 9-plex combining checkpoint and homeostatic cytokine coverage — cover all three dimensions from a single 25 µL plasma sample. For research programs where serial blood draws during the critical post-infusion window yield limited plasma volume, this per-panel volume efficiency is essential.

Inquire About CAR-T Panels View Panel Configurations

The Three Dimensions of CAR-T Cell Biology

CAR-T cell research engages three interconnected but analytically distinct biological dimensions. Understanding which dimension(s) a given study addresses determines panel selection.

 CAR-T Biomarker Dimensions
Inflammatory / CRS dimension: CAR-T cells secrete GM-CSF upon activation, which stimulates myeloid cells to produce IL-6 — the central mediator of the systemic inflammatory response. TNF-α and IL-1β amplify endothelial activation and vascular permeability. IL-10 provides counter-regulatory feedback. The CRS cytokine network is not a single-analyte phenomenon — measuring IL-6 alone misses the upstream GM-CSF signal and the IL-1β-mediated endothelial pathway. The 7-Plex Panel 2 captures this network simultaneously.
Immune checkpoint / exhaustion dimension: within days of infusion, CAR-T cells upregulate PD-L1, CTLA-4, LAG3, and TIGIT. These soluble checkpoint proteins, shed into circulation, reflect the membrane expression levels that define the transition from functional effector to exhausted bystander. CD28 is the co-stimulatory receptor incorporated into second-generation CAR constructs — its soluble form may reflect CAR-T activation state. The 7-Plex Panel 1 captures this checkpoint network.
Cytotoxic effector / persistence dimension: Granzyme B and Perforin are the direct molecular evidence that CAR-T cells are actively killing target cells. IL-7 and IL-15 are homeostatic cytokines supporting CAR-T survival and memory formation. IL-2 reflects autocrine CAR-T proliferation signaling. The 8-Plex captures effector function; the 9-Plex adds the homeostasis signals that determine CAR-T persistence.

Why Multiplex Matters for CAR-T Research

Serial blood sampling during the post-infusion window yields limited plasma — typically 100–200 µL per timepoint that must support multiple assays. MSD requires 25 µL per panel regardless of plex level, enabling all four CAR-T panels from a single 100 µL plasma aliquot. Beyond volume efficiency, multiplex measurement captures the coordinated biology: the ratio of Granzyme B to IL-10 may reflect the balance between killing and immunosuppression; the temporal relationship between GM-CSF elevation and IL-6 elevation informs CRS mechanism research; and checkpoint upregulation coincident with declining Granzyme B may mark the functional exhaustion inflection point that single-analyte assays miss.

CAR-T Monitoring Panel Configurations

Panel	Plex	Analytes	Primary Application
CAR-T 7-Plex Panel 1	7	IFN-γ, TNF-α, TIGIT, PD-L1/B7-H1, CD28, CTLA-4, LAG3	Immune checkpoint dynamics; T-cell functional state
CAR-T 7-Plex Panel 2	7	GM-CSF, IFN-γ, IL-10, IL-6, TNF-α, IL-1β, MCP-1	CRS cytokine profiling; inflammatory cascade
CAR-T 8-Plex	8	Granzyme B, IFN-γ, IL-2, IL-6, TNF-α, Perforin, IL-12p70, IP-10	Cytotoxic effector function; innate immune bridge
CAR-T 9-Plex	9	Granzyme B, IFN-γ, IL-15, IL-7, TNF-α, PD-L1/B7-H1, CD40L (soluble), IL-18, LAG3	Combined effector + checkpoint + homeostatic cytokine coverage

Panels can be combined from the same plasma sample — 25 µL each, 100 µL total for all four. ICANS (neurotoxicity) research may benefit from adding NfL and GFAP via U-PLEX custom configuration. All services are for research use only; not for clinical decision-making.

Panel Selection — Matching Configuration to Research Question

Research Question	Recommended Panel(s)	Rationale
Inflammatory response characterization	7-Plex Panel 2 + 8-Plex	Panel 2 captures core CRS cytokines including GM-CSF (upstream driver) and IL-6; 8-Plex adds Granzyme B/Perforin and IP-10 (endothelial activation)
CAR-T functional state & exhaustion	7-Plex Panel 1 + 9-Plex	Panel 1 captures checkpoint dynamics (PD-L1, CTLA-4, LAG3, TIGIT, CD28); 9-Plex adds IL-7/IL-15 (persistence signals) and CD40L
CAR-T cytotoxic activity	8-Plex or 9-Plex	Both include Granzyme B and Perforin — direct molecular readout of CAR-T cell killing. 8-Plex adds IL-2 + IP-10; 9-Plex adds IL-7/IL-15 + CD40L
Comprehensive CAR-T biology	All 4 panels	100 µL total. Captures CRS, checkpoint, effector, and persistence dimensions from a single blood draw
ICANS (neurotoxicity) research	7-Plex Panel 2 + 8-Plex + NfL/GFAP add-on	CRS cytokines + IP-10 + astrocyte/neuronal injury markers via U-PLEX add-on

Service Details

Service Package

Item	Full Service	Notes
Sample Processing	Included	Serial timepoint coordination for longitudinal studies
Standard Curve	8-point, all analytes	Per-panel, per-plate calibration
QC Samples	Multi-level, duplicate	Low, medium, high levels per analyte
Data Report	Quantitative + temporal plots	Per-analyte time courses with QC metrics
Raw ECL Data	Included	Analysis-ready formats

For Research Use Only. Not for clinical use. Assays use manufacturer-validated MSD reagents with documented QC protocols.

How to Get Started

Select Panels

Choose the panel configuration matching your research dimensions — CRS, checkpoint dynamics, effector function, or all three.

Collect & Ship

EDTA plasma, processed within 1 hour, frozen at −80°C. 25 µL per panel. Document collection timepoints and concomitant medications.

Receive CAR-T Profile

Receive quantitative cytokine, checkpoint, and effector data with temporal plots and QC documentation for research publications.

Electrochemiluminescence for CAR-T Cell Monitoring

Advantages for CAR-T Biomarker Profiling

Three dimensions from one sample: CRS cytokines (7-Plex Panel 2), immune checkpoints (7-Plex Panel 1), and cytotoxic effectors (8/9-Plex) measured from 75 µL plasma — capturing the coordinated CAR-T biology that single-analyte measurement cannot.
Wide dynamic range for CRS cytokines: IL-6 can rise from <10 pg/mL pre-infusion to >10,000 pg/mL during peak CRS. MSD's 4-5 log dynamic range captures both extremes in one run without dilution.
Within-well ratio measurement: Granzyme B/IL-10 ratio reflects cytotoxic-vs-immunosuppressive balance; measured in the same well for superior precision vs. separate ELISA wells.
Serial sampling from 25 µL per panel: post-infusion sampling (Days 1-28) is plasma-limited. 25 µL per panel enables running all three dimensions at every timepoint from a single blood draw.

CAR-T Monitoring Specifications

Panels4 configurations, 7-9 plex

TechnologyMSD V-PLEX

Sample Volume25 µL per panel

All 4 Panels100 µL total plasma

Sample MatrixEDTA Plasma

Dynamic Range4-5 logs per analyte

Throughput40 samples/plate (duplicate)

SpeciesHuman

MSD vs ELISA for CAR-T Cytokine Measurement

Practical advantages for serial post-infusion monitoring

Dynamic Range (IL-6) MSD

Sample Volume Efficiency MSD

Within-Panel Ratio Precision MSD

CRS Cytokine Panel Coverage MSD

For research use only. CRS grading and clinical cytokinemia thresholds are not for diagnostic use.

Your CAR-T Monitoring Data Package

CAR-T biomarker report — cytokine, checkpoint, and effector molecule concentrations with per-analyte QC metrics (Excel + PDF)
Temporal profiling — serial timepoint plots across the post-infusion window showing CRS kinetics, checkpoint evolution, and effector function trajectories
Raw ECL data — per-well signal values, plate maps, standard curve parameters (4PL logistic fit, R², backfit accuracy)
Panel-specific ratio metrics — GM-CSF/IL-6, Granzyme B/IL-10, and other biologically relevant ratios computed from within-well measurements
Methods summary — with CAR-T panel composition tables, post-infusion timepoint documentation, and QC thresholds for CRS cytokine ranges

Why MSD Excels for CAR-T Biomarker Monitoring

Three biological dimensions in one platform: CRS cytokines (7-Plex Panel 2), immune checkpoints (Panel 1), and cytotoxic effectors (8/9-Plex) measured from 100 µL plasma on the same instrument — no cross-platform variability confounding the relationships between these interconnected biological processes
GM-CSF→IL-6 axis captured in a single panel: 7-Plex Panel 2 measures both the upstream driver (GM-CSF from CAR-T cells) and the downstream mediator (IL-6 from myeloid cells) simultaneously — enabling temporal analysis of the CRS initiation cascade
Within-well effector-to-suppression ratios: Granzyme B/IL-10 measured in the same well eliminates cross-well CV — analytically superior for tracking the functional balance between CAR-T killing and immunosuppressive feedback during the post-infusion period
Optional neurotoxicity add-on: NfL and GFAP via U-PLEX custom add-on for ICANS research — complementing CRS cytokine data with neural injury biomarkers from the same sample
25 µL per panel — serial sampling from limited post-infusion plasma: Days 1-28 post-infusion require frequent blood draws with limited plasma volume. All four CAR-T panels run from 100 µL total — enabling comprehensive multi-dimensional profiling at every timepoint

Supporting Publications

Neelapu, S.S. et al. (2017) New England Journal of Medicine. 377(26):2531-2544. "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma." DOI: 10.1056/NEJMoa1707447 · PMID: 29226797 — ZUMA-1 trial with CRS cytokine profiling data including IL-6, GM-CSF, and IFN-γ.
Maude, S.L. et al. (2018) New England Journal of Medicine. 378(5):439-448. "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia." DOI: 10.1056/NEJMoa1709866 · PMID: 29385370 — ELIANA trial demonstrating CAR-T cytokine dynamics in pediatric ALL.
Teachey, D.T. et al. (2016) Cancer Discovery. 6(6):664-679. "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy." DOI: 10.1158/2159-8290.CD-16-0040 · PMID: 27076371 — Multiplex cytokine profiling for CRS prediction and grading.
Giavridis, T. et al. (2018) Nature Medicine. 24(6):731-738. "CAR T cell-induced cytokine release syndrome is mediated by macrophages and abrogated by IL-1 blockade." DOI: 10.1038/s41591-018-0041-7 · PMID: 29808005

For Research Use Only. This CAR-T monitoring panel service is intended for research and investigational use only — including preclinical studies, cohort research, and therapeutic development. It is not intended for clinical diagnostic procedures or individual patient management. Data generated should not be used as the sole basis for any clinical decision. Results should be interpreted in the context of all available research data by qualified investigators. CAR-T monitoring panels use manufacturer-validated MSD reagents with documented QC protocols.

Frequently Asked Questions

What is the advantage of measuring GM-CSF alongside IL-6 for CAR-T cytokine profiling?

IL-6 is the downstream mediator of the systemic inflammatory response. GM-CSF is increasingly recognized as an upstream driver — activated CAR-T cells secrete GM-CSF, which stimulates myeloid cells to produce IL-6. This GM-CSF→IL-6 axis means GM-CSF elevation may precede IL-6 elevation in some research contexts, providing an earlier signal. The CAR-T 7-Plex Panel 2 measures both simultaneously, enabling research into the temporal relationship between GM-CSF and IL-6 during CAR-T cell activation. For research use only.

How do Granzyme B and Perforin inform CAR-T effector function in research?

Granzyme B and Perforin are the primary cytotoxic effector molecules of CAR-T cells. Perforin forms pores in the target cell membrane; Granzyme B enters through these pores and initiates apoptosis. Their presence in plasma reflects active CAR-T degranulation — molecular evidence that CAR-T cells are killing target cells, not merely activated. The ratio of Granzyme B to immunosuppressive cytokines (e.g., Granzyme B:IL-10) is explored in research contexts as a functional efficacy metric. The 8-Plex and 9-Plex both include Granzyme B and Perforin. For research use only.

What is the recommended sampling schedule for CAR-T research studies?

A typical research sampling schedule includes: pre-infusion baseline; early phase (Days 1, 3, 5, 7) for CRS cytokine dynamics; mid phase (Days 10, 14, 21, 28) for CAR-T persistence and checkpoint evolution; and long-term follow-up (Months 2, 3, 6) for durability of response. The highest-frequency sampling should span the expected cytokine response window. 25 µL per panel enables running multiple panels at each timepoint from a single blood draw. All services are for research use only.

Can NfL or GFAP be added for neurotoxicity research?

Yes. NfL (neurofilament light) and GFAP are not included in standard CAR-T panels but can be added via U-PLEX custom configuration. NfL reflects axonal injury and GFAP reflects astrocyte activation — both are studied in the context of ICANS (immune effector cell-associated neurotoxicity). Adding these to the CAR-T Panel 2 + 8-Plex combination provides CRS cytokines + effector function + neurotoxicity markers in a comprehensive research panel. For research use only.

How does the MSD CAR-T 7-Plex Panel 1 compare to flow cytometry for checkpoint monitoring?

Flow cytometry measures membrane-bound checkpoint expression on specific cell populations (e.g., PD-L1 on CAR-T cells by gating). The MSD 7-Plex Panel 1 measures the soluble shed forms of these same proteins (sPD-L1, sCTLA-4, sLAG3, sTIGIT, sCD28) in plasma. These are complementary measurements: membrane expression reflects cellular checkpoint status at the moment of staining; soluble forms reflect cumulative shedding into circulation over time and may represent a systemic pool of checkpoint-mediated immune regulation. The panel also includes IFN-γ and TNF-α for concurrent functional context. For comprehensive CAR-T monitoring, some research programs use flow cytometry for cellular phenotyping and MSD for soluble biomarker profiling — complementary data from the same blood draw. For research use only.

Inquiry Basket